

As reported herein is the bispecific antibody as reported herein for use in inhibiting growth of tumor cells expressing CD20. In one embodiment the inhibiting is in the brain.

5 As reported herein is the bispecific antibody as reported herein for use in treating carcinoma. In one preferred embodiment the carcinoma is carcinoma of/in the brain.

As reported herein is the bispecific antibody as reported herein for use in treating lymphoma. In one preferred embodiment the lymphoma is primary central nervous system lymphoma (PCNSL).

10 As reported herein is the bispecific antibody as reported herein for use in treating an autoimmune disease. In one embodiment the autoimmune disease is multiple sclerosis. In one preferred embodiment the autoimmune disease is secondary progressive multiple sclerosis.

15 Another aspect as reported herein is the antibody as reported herein for use in the treatment of multiple sclerosis.

As reported herein is the bispecific antibody as reported herein for use in depleting tumor cells expressing CD20. In one embodiment the depleting is in the brain.

20 As reported herein is the bispecific antibody as reported herein for use in depleting circulating B-cells expressing CD20. In one embodiment the depleting is in the brain.

As reported herein is the bispecific antibody as reported herein for use in depleting brain sequestered B-cells expressing CD20.

As reported herein is the use of the bispecific antibody as reported herein in the manufacture of a medicament.

25 Another aspect as reported herein is use of the antibody as reported herein in the manufacture of a medicament for treatment of multiple sclerosis.

9. The antibody according to any one of claims 1 to 7 for use as a medicament.
 10. The antibody according to any one of claims 1 to 7 for use in the treatment of multiple sclerosis.
 11. Use of the antibody according to any one of claims 1 to 7 in the manufacture of a medicament for treatment of multiple sclerosis.
- 5